Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened vs Standard Teprotumumab in Thyroid Eye Disease
NCT07308964Phase 4Not yet recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of teprotumumab in thyroid eye disease (TED), sponsored by Sheba Medical Center. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07308964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308964.